Preferred-tier access to...

...the eczema medication Eucrisa has grown 95% since June 2017, to 39 million lives. The FDA approved the drug in December 2016, and manufacturer Pfizer has been promoting it as a competitor to Regeneron's Dupixent since then. Dupixent holds preferred-tier status for 92 million covered lives.

SOURCE: MMIT Analytics, as of June 22, 2018